Overview | Alpelisib with fulvestrant for treating hormone receptor ...
...Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults. Last reviewed: 10 August 2022....
https://www.nice.org.uk/guidance/ta816
Testing for PIK3 A/AKT1/PTEN in Hormone Receptor-Positive HER2-Negative ...
...1.Objective and scope This document provides clinical guidance for testing relevant biomarkers for alpelisib and capivasertib eligibility in patients as per NICE recommendations Technology Appraisal (TA816) and (TA11513) to guide treatment decisions for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer....
https://performanceandimprovement.nhs.wales/functions/networks-and-planning/cancer/wcn-documents/genomics/pik25/
ALPELISIB (Piqray) FULVESTRANT
...isib Loperamide for diarrhoea. Oral antihistamine administration may be considered prophylactically, at the initiati. n of treatment with alpelisib. Additionally, antihistamines are recommen....
https://thamesvalleycanceralliance.nhs.uk/wp-content/uploads/2023/11/Alpelisib-Fulvestrant-5.1.pdf
Quick Reference Guide - MRSA Topical Eradication
...Indication Hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced inoperable or metastatic breast cancer in combination with fulvestrant in patients with disease progression after a CDK4/6 inhibitor plus an aromatase inhibitor. (NICE TA816)...
https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2022/10/Alpelisib-Fulvestrant-v1.pdf
8.6.3 Phosphoinositide 3-kinase (PI3K) inhibitors - South & West
...NICE TA816 (August 2022): Alpelisib (Piqray) plus fulvestrant is recommended as an option for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults, only if:...
https://southwest.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-6-miscellaneous-antineoplastics/8-6-3-phosphoinositide-3-kinase-pi3k-inhibitors
Alpelisib with fulvestrant for
...Project Status: Completed URL for project: https://www.nice.org.uk/guidance/ta816 Year Published: 2022 URL for published report: https://www.nice.org.uk/guidance/ta816 English language abstract: An English language summary is available...
https://database.inahta.org/article/30792
North East and North Cumbria Formulary
...Looking for Alpelisib found 2 matches ... Links Link to Drug Section Link to document NICE TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (08.03.04.01)...
https://www.northeastnorthcumbriaformulary.nhs.uk/searchresults.asp?SearchVar=Alpelisib
Nottinghamshire Area Prescribing Committee Formulary
...Approved in accordance NICE TA816 with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in adults. Approved in accordance with NICE TA1122 for untreated EGFR mutation-positive advanced non-small-cell lung cancer, in combination with lazertinib in adults....
https://www.nottinghamshireformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=8&SubSectionRef=08.01.05&SubSectionID=A100
Bedfordshire and Luton Joint Formulary Formulary
...NICE TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer Amivantamab (Rybrevant ®) (350mg concentrate for solution for infusion) Restricted FOR ALL PRESCRIBING ? Blueteq or High cost drug form required ? see link from Formulary homepage....
https://www.bedsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=8&SubSectionRef=08.01.05&SubSectionID=A100
Implementation of circulating tumour DNA (ctDNA) testing in the NHS
...We are writing to you regarding the implementation of circulating tumour DNA (ctDNA) testing in the NHS and the requirement for NHS Trusts to procure and fund blood collection kits locally to enable the ctDNA testing....
https://www.england.nhs.uk/long-read/implementation-of-circulating-tumour-dna-ctdna-testing-in-the-nhs/
Åby Åbyggeby Åbytorp Åhus Åkarp Åkers styckebruk Åkersberga Ålberga Åled Ålem Åmmeberg Åmot Åmotfors Åmsele Åmynnet Åmål Ånge Ånäset Åre Årjäng Årstad Årsunda Åryd Ås Åsa Åsarne Åsarp Åsbro Åsby Åseda Åsele Åselstad Åsen Åsenhöga Åsensbruk Åshammar Åsljunga Åstol Åstorp Åtorp Åtvidaberg